These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 22383748)

  • 1. Racial differences in markers of mineral metabolism in advanced chronic kidney disease.
    Jovanovich A; Chonchol M; Cheung AK; Kaufman JS; Greene T; Roberts WL; Smits G; Kendrick J;
    Clin J Am Soc Nephrol; 2012 Apr; 7(4):640-7. PubMed ID: 22383748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Racial differences in the relationship between vitamin D, bone mineral density, and parathyroid hormone in the National Health and Nutrition Examination Survey.
    Gutiérrez OM; Farwell WR; Kermah D; Taylor EN
    Osteoporos Int; 2011 Jun; 22(6):1745-53. PubMed ID: 20848081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients.
    Bhan I; Powe CE; Berg AH; Ankers E; Wenger JB; Karumanchi SA; Thadhani RI
    Kidney Int; 2012 Jul; 82(1):84-9. PubMed ID: 22398410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
    Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
    Yin C; Cheng C; Wang J; Zhang L; Purrunsing Y; Yang G; Zeng M; Huang H; Ren W; Ye Y; Ma H; Xing C; Wang N
    Clin Nephrol; 2020 Feb; 93(2):65-76. PubMed ID: 31793871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 25-hydroxyvitamin D concentration is inversely associated with serum MMP-9 in a cross-sectional study of African American ESRD patients.
    Wasse H; Cardarelli F; De Staercke C; Hooper C; Veledar E; Guessous I
    BMC Nephrol; 2011 May; 12():24. PubMed ID: 21600051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum 25-hydroxyvitamin D as an independent determinant of 1-84 PTH and bone mineral density in non-diabetic predialysis CKD patients.
    Tomida K; Hamano T; Mikami S; Fujii N; Okada N; Matsui I; Nagasawa Y; Moriyama T; Ito T; Imai E; Isaka Y; Rakugi H
    Bone; 2009 Apr; 44(4):678-83. PubMed ID: 19111635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in 25-Hydroxyvitamin D Clearance by eGFR and Race: A Pharmacokinetic Study.
    Hsu S; Zelnick LR; Lin YS; Best CM; Kestenbaum B; Thummel KE; Rose LM; Hoofnagle AN; de Boer IH
    J Am Soc Nephrol; 2021 Jan; 32(1):188-198. PubMed ID: 33115916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 25-Hydroxyvitamin D, parathyroid hormone, and mortality in black and white older adults: the health ABC study.
    Kritchevsky SB; Tooze JA; Neiberg RH; Schwartz GG; Hausman DB; Johnson MA; Bauer DC; Cauley JA; Shea MK; Cawthon PM; Harris TB; Rubin SM; Tylavsky FA; Houston DK;
    J Clin Endocrinol Metab; 2012 Nov; 97(11):4156-65. PubMed ID: 22942386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin D metabolites and bone mineral density: The multi-ethnic study of atherosclerosis.
    van Ballegooijen AJ; Robinson-Cohen C; Katz R; Criqui M; Budoff M; Li D; Siscovick D; Hoofnagle A; Shea SJ; Burke G; de Boer IH; Kestenbaum B
    Bone; 2015 Sep; 78():186-93. PubMed ID: 25976951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal Evolution of Markers of Mineral Metabolism in Patients With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.
    Isakova T; Cai X; Lee J; Mehta R; Zhang X; Yang W; Nessel L; Anderson AH; Lo J; Porter A; Nunes JW; Negrea L; Hamm L; Horwitz E; Chen J; Scialla JJ; de Boer IH; Leonard MB; Feldman HI; Wolf M;
    Am J Kidney Dis; 2020 Feb; 75(2):235-244. PubMed ID: 31668375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Revisiting racial differences in ESRD due to ADPKD in the United States.
    Murphy EL; Dai F; Blount KL; Droher ML; Liberti L; Crews DC; Dahl NK
    BMC Nephrol; 2019 Feb; 20(1):55. PubMed ID: 30764782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermediate outcomes by race and ethnicity in peritoneal dialysis patients: results from the 1997 ESRD Core Indicators Project. National ESRD Core Indicators Workgroup.
    Rocco MV; Frankenfield DL; Frederick PR; Pugh J; McClellan WM; Owen WF
    Perit Dial Int; 2000; 20(3):328-35. PubMed ID: 10898051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Relationship Between Intact Parathyroid Hormone and 25-Hydroxyvitamin D in United Kingdom Resident South Asians and Whites: A Comparative, Cross-Sectional Observational Study.
    Coley-Grant D; Jawad M; Ashby HL; Cornes MP; Kumar B; Hallin M; Nightingale PG; Ford C; Gama R
    Horm Metab Res; 2021 Oct; 53(10):672-675. PubMed ID: 34233374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low 25-hydroxyvitamin D levels and mortality in non-dialysis-dependent CKD.
    Navaneethan SD; Schold JD; Arrigain S; Jolly SE; Jain A; Schreiber MJ; Simon JF; Srinivas TR; Nally JV
    Am J Kidney Dis; 2011 Oct; 58(4):536-43. PubMed ID: 21816525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibroblast Growth Factor 23 (FGF 23) and intact parathyroid hormone (iPTH) as markers of mineral bone disease among Nigerians with non-diabetic kidney disease.
    Raji YR; Ajayi SO; Adeoye AM; Amodu O; Tayo BO; Salako BL
    Afr Health Sci; 2022 Mar; 22(1):344-351. PubMed ID: 36032486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Racial-ethnic differences in chronic kidney disease-mineral bone disorder in youth on dialysis.
    Laster M; Soohoo M; Streja E; Elashoff R; Jernigan S; Langman CB; Norris KC; Salusky IB; Kalantar-Zadeh K
    Pediatr Nephrol; 2019 Jan; 34(1):107-115. PubMed ID: 30267239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of CKD-MBD in pre-dialysis patients using biochemical markers in Enugu, South-East Nigeria.
    Okoye JU; Arodiwe EB; Ulasi II; Ijoma CK; Onodugo OD
    Afr Health Sci; 2015 Sep; 15(3):941-8. PubMed ID: 26957985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast Growth Factor 23 and Risk of CKD Progression in Children.
    Portale AA; Wolf MS; Messinger S; Perwad F; Jüppner H; Warady BA; Furth SL; Salusky IB
    Clin J Am Soc Nephrol; 2016 Nov; 11(11):1989-1998. PubMed ID: 27561289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Race, Mineral Homeostasis and Mortality in Patients with End-Stage Renal Disease on Dialysis.
    Scialla JJ; Parekh RS; Eustace JA; Astor BC; Plantinga L; Jaar BG; Shafi T; Coresh J; Powe NR; Melamed ML
    Am J Nephrol; 2015; 42(1):25-34. PubMed ID: 26287973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.